Liver Cancer Therapeutics Market - Global
Industry Insights, Trends, Outlook, and
Opportunity Analysis 2018-2026
Liver cancer is a type of malignant hepatic tumor in or on the liver, which may cause due to
excessive alcohol intake, diabetes, certain inherited liver diseases, and hepatitis. Symptoms of this
cancer appears only when it is in the advanced stage. The most common type of liver cancer is
hepatocellular carcinoma, which begins in the main type of liver cell. Other types of liver cancer
such as hepatoblastoma and intrahepatic cholangiocarcinoma are less common. Incidence rate of
liver cancer is high in the U.S., owing to prevalence of cirrhosis caused by nonalcoholic fatty liver
disease and chronic hepatitis C. According to American Cancer Society 2017, Liver cancer is the
10th most common cancer and fifth most common cause of death among men in the U.S. Also, it is
the eighth most common cause of death among women. Colorectal cancer is expected to be one of
the precursor for liver cancer. According to International Scholarly Research Network, a clinical
study on Percutaneous Cryoablation of Metastatic Lesions from Colorectal Cancer in 2012:
Efficacy and Feasibility with Survival and Cost-Effectiveness Observations, around 50% of the
patient suffering from colorectal cancer develop liver cancer.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/1591
Liver cancer therapeutics Market – Driver
Increasing research to identify the causes of liver cancer is expected to boost growth of the liver
cancer therapeutics market during the forecast period. For instance, in November, 2014, researchers